BIRC3 and breast cancer: The results demonstrated that KRT5, UGT2B4, MRC1, CD209, and KLRB1 were significantly downregulated in HR+ breast cancer compared to normal breast tissue, whereas BIRC3 and FABP7 showed no significant differences in expression between the two groups (Figure S8).